Last update 01 Nov 2024

Thrombotargets Corp.

Private Company|
North Carolina, United States
|
www.thrombotargets.com

Overview

Tags

Hemic and Lymphatic Diseases
Cardiovascular Diseases
Other Diseases
Monoclonal antibody
Recombinant coagulation factor

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases1
Top 5 Drug TypeCount
Monoclonal antibody1
Recombinant coagulation factor1
Top 5 TargetCount
tissue factor1

Related

10
Drugs associated with Thrombotargets Corp.
TT-173
Target
tissue factor
Mechanism
tissue factor modulators
Active Org.
Thrombotargets Corp. [+1]
Originator Org.
Thrombotargets Corp.
Active Indication
Blood Coagulation Disorders [+2]
Inactive Indication
Burns [+2]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
TT-105
Target-
Mechanism-
Active Org.
Thrombotargets Corp.
Originator Org.
Thrombotargets Corp.
Active Indication
Venous Thrombosis
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
TT-112
Target-
Mechanism-
Active Org.-
Originator Org.
Thrombotargets Corp.
Active Indication-
Inactive Indication
Hemorrhage
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Thrombotargets Corp.
NCT02687399 / Unknown statusPhase 2/3
A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty
NCT02012569 / CompletedPhase 2
A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft
NCT01595360 / CompletedPhase 1
A Phase 1, Randomized, Open, Controlled, Comparative Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction
100 Clinical Results associated with Thrombotargets Corp.
Login to view more data
0 Patents (Medical) associated with Thrombotargets Corp.
Login to view more data
100 Deals associated with Thrombotargets Corp.
Login to view more data
100 Translational Medicine associated with Thrombotargets Corp.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 3 Clinical
Other
8
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
TT-173
 ( tissue factor )		Blood Coagulation Disorders
More
Phase 3
TT-105
Venous Thrombosis
More
Preclinical
TT-115
Blood Coagulation Disorders
More
Pending
TT-124
Blood Coagulation Disorders
More
Pending
TT-310
Central Nervous System Diseases
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free